louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00547742: Correlation of PET-CT Studies With Serum Protein Analysis
Official title: Correlation of PET-CT Studies With Serum Protein Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Carcinomas (Including Squamous Cell and Adenocarcinoma)
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2007-10-23
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients having PET/CT scans

Brief summary: To correlate serum proteomics patterns with PET/CT findings to improve cancer diagnosis, staging, prognosis, and therapy monitoring.


Eligibility criteria: Inclusion Criteria:1. Patients must have a PET/CT study performed at the time of blood collection.

2. Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them. Exclusion Criteria:1. Patients who are not eligible for a PET/CT study.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Dr Andrew Quon
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00638742: A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.
Official title: A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost 0.005%.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Glaucoma
Ocular Hypertension
Keywords: Latanoprost Pediatrics Pharmacokinetics Safety
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2008-03-19
Enrollment: 47
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: To evaluate the steady-state systemic plasma concentrations of latanoprost acid following administration of latanoprost 0.005% (1.5 ug) in pediatric and adult subjects with glaucoma or ocular hypertension.

Detailed description: Pharmacokinetics and Safety

Eligibility criteria: Inclusion Criteria:

* This study will enroll pediatric and adult subjects with glaucoma or ocular hypertension receiving treatment with latanoprost in either one or both eyes for at least two weeks.
* The pediatric subjects will be grouped by age (0 to \<3 years, 3 to \<12 years, 12 to 18 years).

Exclusion Criteria:

* Ocular inflammation/infection or a history of ocular inflammation/infection within 3 months prior to the screening visit.
* History of ocular trauma or surgery in either eye within 14-days of the screening visit.
* Use of continuous wear contact lenses.

Primary outcomes:
measure: Plasma latanoprost acid concentrations at steady-state.
timeFrame: 2 weeks
Secondary outcomes:
measure: Adverse events related to systemic exposure of latanoprost
timeFrame: 1 Day
Other outcomes:
Locations:
city: Artesia
country: United States
facility: Pfizer Investigational Site
state: California
city: Atlanta
country: United States
facility: Pfizer Investigational Site
state: Georgia
city: Atlanta
country: United States
facility: Pfizer Investigational Site
state: Georgia
city: North Dartmouth
country: United States
facility: Pfizer Investigational Site
state: Massachusetts
city: Minneapolis
country: United States
facility: Pfizer Investigational Site
state: Minnesota
city: Durham
country: United States
facility: Pfizer Investigational Site
state: North Carolina
city: Koebenhavn OE
country: Denmark
facility: Pfizer Investigational Site
city: Catania
country: Italy
facility: Pfizer Investigational Site
city: Coimbra
country: Portugal
facility: Pfizer Investigational Site
city: Lisboa
country: Portugal
facility: Pfizer Investigational Site
city: Mayfair West
country: South Africa
facility: Pfizer Investigational Site
city: Madrid
country: Spain
facility: Pfizer Investigational Site
city: Madrid
country: Spain
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT06612242: Early vs. Late Tracheostomy in Patients With Guillain -Barre Syndrome
Official title: Early vs. Late Tracheostomy in Patients With Guillain -Barre Syndrome: Comparison of Clinical Outcomes- a Retrospective Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Guillain Barre Syndrome
Mechanical Ventilation
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
First posted: 2024-09-25
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients aged 18--99 who were admitted to the general intensive care unit from January 2012 to September 2024 with a diagnosis of Guillain-Barre syndrome who required mechanical ventilation and underwent tracheostomy during ICU stay

Brief summary: Tracheostomy is one of the most common procedures in the intensive care unit in patients who need prolonged invasive mechanical ventilation. There is controversy in the literature regarding the ideal timing for performing tracheostomy in critically ill patients. Early tracheostomy may be associated with a decrease in ventilation days and hospitalization. We would like to investigate whether in ventilated patients with Guillain Barre syndrome, early tracheostomy will be associated with decreased ventilation days, decreased mortality and shorter hospital and ICU length of stay.


Eligibility criteria: Inclusion Criteria: All patients aged 18--99 who were admitted to the general intensive care unit from January 2012 to September 2024 with a diagnosis of Guillain-Barre syndrome who required mechanical ventilation and underwent tracheostomy during ICU stay.

-

Exclusion Criteria: Missing recoreded data

-

Primary outcomes:
measure: ventilation days
timeFrame: 1 year from intubation
Secondary outcomes:
Other outcomes:
Locations:
city: Kfar Saba
country: Israel
facility: Meir Medical Center
Study officials:
References:
Clinical trial NCT03303742: Feather Edge Versus Deep Chamfer Finish Line Marginal Design in Complete Coverage Bruxzir Zirconia Crowns
Official title: Evaluation of Patient Satisfaction, Color Difference, Marginal Integrity and Survival of Bruxzir Zirconia Complete Coverage Crowns With Feather Edge Versus Deep Chamfer Finish Line Marginal Design.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Premolars Need Full Coverage Restoration
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2017-10-06
Enrollment: 20
Sex: ALL
Minimum age (years): 19
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluation of patient satisfaction, color difference, marginal integrity and survival of Bruxzir Zirconia complete coverage crowns with feather edge versus deep chamfer finish line marginal design.

(Randomised Controlled Trial)


Eligibility criteria: Inclusion Criteria:

* 19-50 years.
* Males or females.
* Co-operative patients approving to participate in the trial.

Exclusion Criteria:

* Patients younger than 19 years old
* Disabilities
* Systemic diseases or severe medically compromised
* Lack of compliance of the patient contributed in the study

Primary outcomes:
measure: patient satisfaction
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Sara Hussein Elbasha
Study officials:
References:
Clinical trial NCT06924242: Thyroid Cancer in Surgical Treated Multinodular Goiter
Official title: Thyroid Cancer in Surgically Treated Multinodular Goiter: Incidence and Histopatological Outcomes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Goiter, Nodular
Total Thyroidectomy
Thyroid Cancer
Lead sponsor: University of Foggia
Sponsor class: OTHER
First posted: 2025-04-11
Enrollment: 223
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients of both sex with cancer incidence in multinodular thyroid goiter who underwent surgery in the same center

Brief summary: This study aims to investigate, based on existing knowledge, the incidence of occult thyroid carcinoma in a cohort of patients with MNG, providing new insights into the prevalence and characteristics of thyroid malignancies in MNG. It seeks to contribute to optimizing diagnostic evaluations for patients with multinodular goiter.

Detailed description: This retrospective study included patients with a preoperative diagnosis of multinodular goiter who underwent total or partial thyroidectomy from January 2018 to May 2024 at the Department of Medical and Surgical Sciences at the University Hospital "Ospedali Riuniti" in Foggia. The study's objective was to investigate the incidence of thyroid carcinoma in patients undergoing thyroidectomy for MNG, also analyzing associated demographic and clinical variables.

Eligibility criteria: Inclusion Criteria:

* patients diagnosed with multinodular goiter via thyroid ultrasound, with or without FNA cytology.
* patients who underwent surgery.
* availability of complete clinical data

Exclusion Criteria:

* history of thyroid carcinoma or other thyroid neoplasms.
* not completed postoperative follow up.
* patients with preoperative FNA results indicating malignancy (TIR 4-5), suspicion of malignancy (TIR 3), or indeterminate significance (TIR 1)

Primary outcomes:
measure: incidence of occult thyroid carcinoma
timeFrame: 6 years
Secondary outcomes:
Other outcomes:
Locations:
city: Foggia
country: Italy
facility: University of Foggia
state: FG
Study officials:
References:
Clinical trial NCT02886442: A Pilot Evaluation of Adhesives and How They Are Impacted by Output
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ileostomy-stoma
Lead sponsor: Coloplast A/S
Sponsor class: INDUSTRY
First posted: 2016-09-01
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This study investigates the impact of real output on the adhesion of two adhesives.


Eligibility criteria: Inclusion Criteria:

1. Have given written informed consent
2. Be at least 18 years of age and have full legal capacity
3. Have had an ileostomy for more than one year
4. Have intact skin on the area used in the evaluation
5. Has an ileostomy with a diameter up to (≤) 35 mm
6. Have a peristomal area accessible for application of patches/adhesive strips (assessed by investigating scientist) -

Exclusion Criteria:

1. Currently receiving or have within the past 2 month received radio- and/or chemotherapy
2. Currently receiving or have within the past month received topical steroid treatment in the peristomal skin area or systemic steroid (tablet/injection) treatment.
3. Are pregnant or breastfeeding
4. Having dermatological problems in the peristomal- or abdominal area (assessed by investigating scientist)
5. Participating in other interventional clinical investigations or have previously participated in this evaluation

Primary outcomes:
measure: Peel force
timeFrame: 12 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Humlebaek
country: Denmark
facility: Coloplast A/S
Study officials:
affiliation: Senior R&D scientist
name: Lene F Nielsen, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03995342: The Correlation and Intervention of Intestinal Flora and Frailty in the Elderly
Official title: The Correlation and Intervention of Intestinal Flora and Frailty in the Elderly
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Frailty Syndrome
Keywords: frailty, flora
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
First posted: 2019-06-24
Enrollment: 300
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The study aim to evaluate the improvement and correlation of soluble dietary fiber (prebiotics) in the frailty of elderly people by a randomized, double-blind, placebo-controlled clinical trial.

Detailed description: 100 healthy controls, 100 pre-frailty and 100 frailty elderly will be included. the healthy controls will be received no intervention. The pre-frailty will be randomized at a 1：1 ratio to receive prebiotics (inulin) or placebo (maltodextrin) . The degree of improvements and correlation in frailty will be evaluated three months later.Similarly,the frailty also will be randomized at a 1：1 ratio to receive prebiotics (inulin) or placebo (maltodextrin). The degree of improvements and correlation in frailty will be evaluated three months later.

Eligibility criteria: Inclusion Criteria:

* Age ≥65 years;
* Can get up from a chair and walk 6 meters
* Clearly consciousness, able to read or use words to express and communicate without difficulty
* Agree and accept the study plan

Exclusion Criteria:

* Acute and chronic inflammatory disease of the intestine within 3 months
* Use of antibiotics, probiotics, prebiotics or synthetics, laxatives or diarrhea medications, proton pump inhibitors or gastric motility drugs within 1 month
* Dementia
* mental illness or blindness
* acute infection
* cancer

Primary outcomes:
measure: Improvement of frailty
timeFrame: 3 months
Secondary outcomes:
measure: Diversity analysis of intestinal flora
timeFrame: 3 months
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Xijing Hospital
state: Shaanxi
Study officials:
affiliation: Director of geriatrics
name: Wang xiao ming
role: STUDY_CHAIR
References:
Clinical trial NCT02271542: Identification of Polymorphisms Involved in the Metabolism of Propofol
Official title: Identification of Polymorphisms Involved in the Metabolism of Propofol
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: UGT1A1*28 Polymorphism
Keywords: Propofol
Polymorphism
UGT1A9
CYP2B6
Lead sponsor: TC Erciyes University
Sponsor class: OTHER
First posted: 2014-10-22
Enrollment: 300
Sex: ALL
Minimum age (years): 1
Maximum age (years): 85
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Identification of Polymorphisms Involved in the Metabolism of Propofol

Detailed description: Propofol inside and outside the operating room during anesthesia is a drug widely used. In terms of efficacy and side effect profile of propofol knows if properties are insufficient data on the metabolism. Propofol typically undergoes biotransformation by microsomal enzymes in the liver. For most of the administered dose, takes place glucuronidation by UGT1A9 enzyme, while the remaining portion is oxidized with CYP2B6 hydroxylation reactions. However, these enzymes are involved in the metabolism of propofol are enzymes highly polymorphic. Polymorphisms occurring in these enzymes; the effects of propofol, side effects and drug needs to show individual differences in terms of causes. Determination of the genetic background of individuals and personal anesthetic regimen improved. Thus, useful person drug resistance, increased incidence of side effects can be reduced. In particular, be aware of some mutations, such as propofol infusion syndrome mortal side effects can be prevented. The main purpose of this study, these individual differences are thought to be the cause of polymorphic variation in UGT1A9 and CYP2B6 gene to determine. Especially in the UGT1A9 gene mutations that may be associated with ethnic structure can be observed. In Caucasian, African-American communities and polymorphisms of this gene has been shown in Japanese. So all of them as a result of the genetic structure of any society can be considered as its own. Therefore, this study aimed to determine the genetic polymorphism of Turkish society has.Physiological factors such as age and sex between persons of different answers to the causes of propofol. Another object of this study was the identification of these factors can lead to different answers which is to present the relationship between polymorphisms.

Eligibility criteria: Inclusion Criteria:

* Patients who used propofol for induction onl
* Between the ages of 1-85

Exclusion Criteria:

* Patients taking drugs that may affect the metabolism of propofol (exp.Ketamine)
* Smoking and Alcohol users
* Patients using herbal medicines

Primary outcomes:
measure: Polymorphism
timeFrame: 60 minutes after induction
Secondary outcomes:
Other outcomes:
Locations:
city: Kayseri
country: Turkey
facility: Erciyes University
Study officials:
affiliation: TC Erciyes University
name: Halil AKBULUT, Resident
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00296842: Prevention of Posttraumatic Stress Symptoms and Behavioral Problems in Children After Road Traffic Accidents: a Randomized Controlled Trial
Official title: Prevention of Posttraumatic Stress Symptoms and Behavioral Problems in Children and Adolescents After Road Traffic Accidents: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Injury
Keywords: posttraumatic stress disorder
children
injury
road traffic accident
Lead sponsor: University Children's Hospital, Zurich
Sponsor class: OTHER
First posted: 2006-02-27
Enrollment: 99
Sex: ALL
Minimum age (years): 7
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to study the effectiveness of an early psychological intervention 7-10 days after a road traffic accident on posttraumatic stress and behavior of children and adolescents

Detailed description: Within a randomized controlled design the effects of a brief psychological intervention (child, parents) after a road traffic accident shall be examined in a sample of 100 children and adolescents. After a baseline assessment 7-10 days after the accident participants are randomly assigned to an intervention or a control group. Both are re-assessed at 2 and 6 months after the accident by means of standardized questionnaires assessing posttraumatic stress symptoms, depression, and behavior.

Eligibility criteria: Inclusion Criteria:

Age 7-16 y Command of German language Road traffic accident inpatient or outpatient treatment at the University Children's Hospital Zurich no pretraumatic developmental delay

Exclusion Criteria:

severe head injury No command of the German language Age below 7 y or above 16 y Other major systemic illness

Primary outcomes:
measure: CAPS-CA
timeFrame: 10 days, 2 months, 6 months after intervention
measure: CBCL
timeFrame: 10 days, 2 months, 6 months after intervention
measure: DIKJ
timeFrame: 10 days, 2 months, 6 months after intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Children's Hospital, Psychosomatic and Psychiatry
Study officials:
affiliation: University Children's Hospital
name: Markus A Landolt, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Zehnder D, Meuli M, Landolt MA. Effectiveness of a single-session early psychological intervention for children after road traffic accidents: a randomised controlled trial. Child Adolesc Psychiatry Ment Health. 2010 Feb 8;4:7. doi: 10.1186/1753-2000-4-7.
Clinical trial NCT01113242: Neuropsychological Assessment of Cognitive Decline in Patients With a Definite Parkinson's Disease
Official title: Characteristics of Cognitive Decline During Parkinson's Disease in the Elderly
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Parkinson Disease Dementia
Keywords: Parkinson Disease Dementia
Observational
Case control
Neuropsychological assessment
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2010-04-29
Enrollment: 40
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with idiopathic PD are issued from an ambulatory following at the department of Geriatrics

Brief summary: Cognitive disorders in Parkinson's disease (PD) are not as obvious as cognitive disorders in Alzheimer disease and their diagnosis tends to be delayed. If neuropsychological assessment of cognitive decline in Parkinson's disease is well established, the thresholds of cognitive testing corresponding to a dementia are unknown. Recently, new diagnosis criteria of dementia associated with PD have been proposed by the movement disorder society. In this study two groups of patients with idiopathic PD will be separated and compared according to their Mini Mental State Examination (MMSE) score (upper or lower than 26). Included patients will have clinically idiopathic PD, will be over 65 years old and will present cognitive complain. Cognitive and mood disorders as well as motor symptoms will be assessed using validated scales and a neuropsychological assessment dispatched in two visits will be performed . Differences in the distribution of data from the two groups of patients will be assessed in statistically analysis with non parametric tests. The purpose of this study is to determine the most effective tests and their threshold value corresponding to a pathological cognitive decline.


Eligibility criteria: Inclusion Criteria:

* MMSE ≥ 16
* impact of cognitive disorders in daily living
* criteria of the UKPDSBB for PD
* steady state in PD
* benign delusions or treated psychosis are tolerated
* informed consent obtained

Exclusion Criteria:

* dementia from other origin than PD
* cognitive decline without impact on daily living
* MMSE \< 16
* delirium in the last 3 months
* Severe Depression
* Central Anticholinergic medication
* inability to perform the cognitive testing
* major cerebrovascular disease
* inability to give an informed consent (patients with protective measures)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de Gériatrie, Hôpital de la Robertsau, Hôpitaux Universitaires de Strasbourg
Study officials:
affiliation: University Hospital, Strasbourg, France
name: Michèle Kiesmann, MD
role: PRINCIPAL_INVESTIGATOR
References: